10-Q: Cardiff Oncology Reports First Quarter 2025 Financial Results and Provides Clinical Program Update

Cardiff Oncology's Q1 2025 report reveals increased R&D spending and a net loss, but the company believes it has sufficient cash to fund operations into Q1 2027.

Summary

• Cardiff Oncology, a clinical-stage biotechnology company, reported its financial results for the first quarter of 2025.
• The company is focused on developing novel therapies for cancer, particularly leveraging PLK1 inhibition.
• Royalty revenues decreased to $0.1 million from $0.2 million in the same period last year.
• Research and development expenses increased to $10.477 million from $8.008 million year-over-year, driven by costs associated with the CRDF 004 clinical trial and other clinical programs.
• Selling, general, and administrative expenses increased to $4.014 million from $3.130 million year-over-year, primarily due to professional fees.
• The net loss for the quarter was $13.434 million, compared to a net loss of $10.011 million for the same period in 2024.
• As of March 31, 2025, the company had $79.9 million in cash, cash equivalents, and short-term investments.
• Cardiff Oncology believes it has sufficient cash to meet its funding requirements for at least the next 12 months following the issuance date of these financial statements, projecting resources to fund operations into the first quarter of 2027.
• Enrollment of approximately 90 evaluable patients was completed in April 2025 for the CRDF-004 trial.
• The company is supporting an investigator-initiated mPDAC Phase 1b/2 trial of onvansertib in combination with first-line SoC NALIRIFOX, which is now open for enrollment at the University of Kansas Medical Center.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is experiencing increased losses and expenses, it maintains a strong cash position and is progressing with its clinical trials. The outlook is cautiously optimistic, pending further clinical trial results.

Positives

• Cardiff Oncology believes it has sufficient cash to meet its funding requirements for at least the next 12 months following the issuance date of these financial statements.
• The company anticipates its capital resources are sufficient to fund operations into the first quarter of 2027.
• Enrollment of approximately 90 evaluable patients was completed in April 2025 for the CRDF-004 trial.
• The company is supporting an investigator-initiated mPDAC Phase 1b/2 trial of onvansertib in combination with first-line SoC NALIRIFOX, which is now open for enrollment at the University of Kansas Medical Center.

Negatives

• Cardiff Oncology reported a net loss of $13.434 million for Q1 2025, which is greater than the $10.011 million loss in Q1 2024.
• Royalty revenues decreased to $0.1 million from $0.2 million in the same period last year.
• Research and development expenses increased by $2.5 million year-over-year, impacting profitability.
• Selling, general and administrative expenses increased by $0.9 million for the three months ended March 31, 2025, compared to the same period in 2024.

Risks

• The company has incurred net losses since its inception and has negative operating cash flows.
• The company's drug development efforts are in their early stages, and there are many uncertainties involved in developing new drug candidates to market.
• The company may require additional capital to further advance its clinical trial programs and support its other operations, and there is no certainty that additional funding will be available on acceptable terms, or at all.
• Raising additional funds by issuing equity securities may result in additional dilution for the company's stockholders.

Future Outlook

Cardiff Oncology believes it has sufficient cash to meet its funding requirements for at least the next 12 months following the issuance date of these financial statements and expects that its capital resources are sufficient to fund its operations into the first quarter of 2027. The company expects to continue to incur losses and require additional capital to further advance its clinical trial programs and support its other operations.

Management Comments

• The company is focusing its clinical program in indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC).
• The company's clinical development programs incorporate tumor genomics and biomarker assays to refine assessment of patient response to treatment.

Industry Context

Cardiff Oncology operates in the competitive biotechnology industry, focusing on oncology therapeutics. The company's strategy involves targeting tumor vulnerabilities with treatment combinations, which aligns with the broader industry trend of personalized medicine and combination therapies to improve patient outcomes. The development of onvansertib, a PLK1 inhibitor, positions the company within a specific niche of targeted cancer therapies.

Comparison to Industry Standards

• The historical control trials of different drug combinations, including the SoC of FOLFIRI with bevacizumab, in similar patient populations have shown ORR and mPFS of 5 – 13% and ~4.5 – 6.7 months, respectively.
• The company is developing novel therapies across a range of cancers with the greatest unmet medical need.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Employees are impacted by the company's ability to fund operations and continue clinical development programs.
• Patients with cancer may benefit from the development of new therapies.
• The company's financial performance affects its relationships with suppliers and creditors.

Next Steps

• Initiate CRDF-005, a Phase 3, randomized trial with registrational intent, contingent upon the results of CRDF-004.
• Continue supporting the investigator-initiated mPDAC Phase 1b/2 trial of onvansertib in combination with first-line SoC NALIRIFOX.
• Continue enrollment in the Phase 2 investigator-initiated clinical trial in SCLC.
• Analyze data from the Phase 1b investigator-initiated clinical trial in TNBC.

Key Dates

Keywords

Oncology, Onvansertib, Clinical Trials, RAS-mutated mCRC, mPDAC, SCLC, TNBC, PLK1 Inhibition, Biotechnology, Financial Results